Purple Biotech (PPBT) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Purple Biotech, a company listed on NASDAQ/TASE under the symbol PPBT, has reinforced its financial position, boasting a $7.3 million cash balance and expecting multiple clinical data readouts in 2024. The company is focused on developing first-in-class drugs for cancers with high unmet medical needs, including promising candidates for pancreatic cancer and a preclinical tri-specific immuno-engagers platform. With a lean global operation, Purple Biotech anticipates a cash runway into the third quarter of 2025, suggesting a strong footing for upcoming clinical trials and drug development initiatives.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
